Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2016

Open Access 01-12-2016 | Study protocol

The Cognition and Affect after Stroke - a Prospective Evaluation of Risks (CASPER) study: rationale and design

Authors: Elles Douven, Syenna H. J. Schievink, Frans R. J. Verhey, Robert J. van Oostenbrugge, Pauline Aalten, Julie Staals, Sebastian Köhler

Published in: BMC Neurology | Issue 1/2016

Login to get access

Abstract

Background

Cognitive impairment and neuropsychiatric syndromes, like depression and apathy, are frequent residual consequences of stroke. These have a large impact on quality of life and long-term prognosis. Several factors are involved in the development of these residual syndromes, although their exact role and their interrelationships remain still rather unclear. The Cognition and Affect after Stroke: a Prospective Evaluation of Risks (CASPER) study has been primarily designed to examine whether stroke-specific (e.g. lesion location, volume, type, severity), cerebrovascular and neurodegenerative (e.g. white matter changes, atrophy, microbleeds, perivascular spaces), inflammatory, endothelial, and (epi)genetic markers are associated with cognitive impairment, post-stroke depression, and post-stroke apathy, and whether they predict their course over 12 months. The secondary aims are to investigate how the above-mentioned markers interact with each other, and to determine if patients with apathy and depression after stroke differ in pathogenesis, course, and outcome (e.g. functional outcome, neurocognitive performance, quality of life).

Methods/design

CASPER is a 1-year prospective clinical cohort follow-up study in 250 stroke patients recruited at the neurological in- and outpatient services at Maastricht University Medical Center (MUMC+, Maastricht, The Netherlands), and Zuyderland Medical Center (Sittard and Heerlen, The Netherlands). At baseline (3 months post-stroke), a neuropsychological assessment, neuropsychiatric interview, blood sample, and brain magnetic resonance imaging (MRI) scan are conducted. Assessment of neuropsychiatric and neurocognitive status are repeated 6 and 12 months later.

Discussion

The CASPER study investigates stroke-specific, vascular, neurodegenerative, inflammatory, and genetic markers of the development of vascular cognitive impairment, depression, and apathy after stroke. This creates the possibility to study not only the contribution of these individual markers but also their joint contribution, which differentiates this study from earlier stroke cohorts who lacked long-term follow-up data, a large sample size, an extensive MRI protocol, and markers from the blood. The knowledge we derive from this study might help in identifying markers that are associated with, or can predict the onset, maintenance, and progression of vascular cognitive impairment, depression, and apathy after stroke, and could provide new insights into possibilities for treatment and rehabilitation that result in better functional outcome after stroke.

Trial registration

ClinicalTrials.gov NCT02585349
Literature
1.
Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383(9913):245–55.CrossRefPubMedPubMedCentral
2.
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380(9859):2095–128.CrossRef
3.
Struijs JN, van Genugten ML, Evers SM, Ament AJ, Baan CA, van den Bos GA. Modeling the future burden of stroke in the Netherlands impact of aging, smoking, and hypertension. Stroke. 2005;36(8):1648–55.CrossRefPubMed
4.
Jorge RE, Starkstein SE, Robinson RG. Apathy following stroke. Can J Psychiatr. 2010;55(6):350–4.
5.
van Dalen JW, van Charante EPM, Nederkoorn PJ, van Gool WA, Richard E. Poststroke apathy. Stroke. 2013;44(3):851–60.CrossRefPubMed
6.
Carod-Artal J, Egido JA, González JL, De Seijas EV. Quality of life among stroke survivors evaluated 1 year after stroke: experience of a stroke unit. Stroke. 2000;31(12):2995–3000.CrossRefPubMed
7.
Ayerbe L, Ayis S, Wolfe CD, Rudd AG. Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis. Br J Psychiatry. 2013;202(1):14–21.CrossRefPubMed
8.
O'Brien J, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB. Vascular cognitive impairment. Lancet Neurol. 2003;2(2):89–98.CrossRefPubMed
9.
Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009;8(11):1006–18.CrossRefPubMed
10.
Sachdev P, Brodaty H, Valenzuela M, Lorentz L, Looi J, Berman K, Ross A, Wen W, Zagami A. Clinical determinants of dementia and mild cognitive impairment following ischaemic stroke: the Sydney Stroke Study. Dement Geriatr Cogn Disord. 2006;21(5):275–83.CrossRefPubMed
11.
Pohjasvaara T, Mäntylä R, Salonen O, Aronen HJ, Ylikoski R, Hietanen M, Kaste M, Erkinjuntti T. How complex interactions of ischemic brain infarcts, white matter lesions, and atrophy relate to poststroke dementia. Arch Neurol. 2000;57(9):1295–300.CrossRefPubMed
12.
Kokmen E, Whisnant J, O'Fallon W, Chu C-P, Beard C. Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960–1984). Neurology. 1996;46(1):154–9.CrossRefPubMed
13.
Richards M, Brayne C. What do we mean by Alzheimer’s disease? BMJ. 2010;341(7778):865–7.
14.
Spalletta G, Bossu P, Ciaramella A, Bria P, Caltagirone C, Robinson R. The etiology of poststroke depression: a review of the literature and a new hypothesis involving inflammatory cytokines. Mol Psychiatry. 2006;11(11):984–91.CrossRefPubMed
15.
Rothenburg LS, Herrmann N, Swardfager W, Black SE, Tennen G, Kiss A, Gladstone DJ, Ween J, Snaiderman A, Lanctôt KL. The relationship between inflammatory markers and post stroke cognitive impairment. J Geriatr Psychiatry Neurol. 2010;23(3):199–205.CrossRefPubMed
16.
Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C, Emsley HC, Forconi S, Hopkins SJ, Masotti L. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP pooling project members. Stroke. 2005;36(6):1316–29.CrossRefPubMed
17.
Tzikas S, Schlak D, Sopova K, Gatsiou A, Stakos D, Stamatelopoulos K, Stellos K, Laske C. Increased myeloperoxidase plasma levels in patients with Alzheimer's disease. J Alzheimers Dis. 2014;39(3):557–64.PubMed
18.
Rajagopalan S, Brook R, Rubenfire M, Pitt E, Young E, Pitt B. Abnormal brachial artery flow-mediated vasodilation in young adults with major depression. Am J Cardiol. 2001;88(2):196–8.CrossRefPubMed
19.
Corsi MM, Licastro F, Porcellini E, Dogliotti G, Galliera E, Lamont JL, Innocenzi PJ, Fitzgerald SP. Reduced plasma levels of P-selectin and L-selectin in a pilot study from Alzheimer disease: relationship with neuro-degeneration. Biogerontology. 2011;12(5):451–4.CrossRefPubMed
20.
Togo T, Akiyama H, Kondo H, Ikeda K, Kato M, Iseki E, Kosaka K. Expression of CD40 in the brain of Alzheimer’s disease and other neurological diseases. Brain Res. 2000;885(1):117–21.CrossRefPubMed
21.
Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, Stijnen T, Hofman A, Witteman JC, Breteler MM. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol. 2004;61(5):668–72.CrossRefPubMed
22.
Tarkowski E, Liljeroth A-M, Minthon L, Tarkowski A, Wallin A, Blennow K. Cerebral pattern of pro-and anti-inflammatory cytokines in dementias. Brain Res Bull. 2003;61(3):255–60.CrossRefPubMed
23.
Komulainen P, Lakka TA, Kivipelto M, Hassinen M, Penttilä IM, Helkala E-L, Gylling H, Nissinen A, Rauramaa R. Serum high sensitivity C-reactive protein and cognitive function in elderly women. Age Ageing. 2007;36(4):443–8.CrossRefPubMed
24.
Schrijvers EM, Schürmann B, Koudstaal PJ, van den Bussche H, Van Duijn CM, Hentschel F, Heun R, Hofman A, Jessen F, Kölsch H. Genome-wide association study of vascular dementia. Stroke. 2012;43(2):315–9.CrossRefPubMed
25.
Chapman J, Wang N, Treves TA, Korczyn AD, Bornstein NM. ACE, MTHFR, factor V Leiden, and APOE polymorphisms in patients with vascular and Alzheimer’s dementia. Stroke. 1998;29(7):1401–4.CrossRefPubMed
26.
Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron. 2010;68(2):270–81.CrossRefPubMed
27.
Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depression after stroke: a systematic review of observational studies. Stroke. 2005;36(6):1330–40.CrossRefPubMed
28.
Hackett ML, Köhler S, T O'Brien J, Mead GE. Neuropsychiatric outcomes of stroke. Lancet Neurol. 2014;13(5):525–34.CrossRefPubMed
29.
Hama S, Yamashita H, Shigenobu M, Watanabe A, Hiramoto K, Kurisu K, Yamawaki S, Kitaoka T. Depression or apathy and functional recovery after stroke. Int J Geriatr Psychiatry. 2007;22(10):1046–51.CrossRefPubMed
30.
Köhler S, Verhey F, Weyerer S, Wiese B, Heser K, Wagner M, Pentzek M, Fuchs A, Köhler M, Bachmann C. Depression, non-fatal stroke and all-cause mortality in old age: a prospective cohort study of primary care patients. J Affect Disord. 2013;150(1):63–9.CrossRefPubMed
31.
Bartoli F, Lillia N, Lax A, Crocamo C, Mantero V, Carrà G, Agostoni E, Clerici M. Depression after stroke and risk of mortality: a systematic review and meta-analysis. Stroke Res Treat. 2013;2013:862978–88.PubMedPubMedCentral
32.
Carson AJ, MacHale S, Allen K, Lawrie SM, Dennis M, House A, Sharpe M. Depression after stroke and lesion location: a systematic review. Lancet. 2000;356(9224):122–6.CrossRefPubMed
33.
Vataja R, Pohjasvaara T, Mäntylä R, Ylikoski R, Leskelä M, Kalska H, Hietanen M, Aronen HJ, Salonen O, Kaste M. Depression–executive dysfunction syndrome in stroke patients. Am J Geriatr Psychiatry. 2005;13(2):99–107.PubMed
34.
Taylor-Piliae RE, Hepworth JT, Coull BM. Predictors of depressive symptoms among community-dwelling stroke survivors. J Cardiovasc Nurs. 2013;28(5):460–7.CrossRefPubMed
35.
van Mierlo ML, van Heugten CM, Post MW, de Kort PL, Visser-Meily JM. Psychological factors determine depressive symptomatology after stroke. Arch Phys Med Rehabil. 2015;96(6):1064–70.CrossRefPubMed
36.
Neubauer H, Petrak F, Zahn D, Pepinghege F, Hägele A-K, Pirkl P-A, Uhl I, Juckel G, Mügge A, Herpertz S. Newly diagnosed depression is associated with increased beta-thromboglobulin levels and increased expression of platelet activation markers and platelet derived CD40-CD40L. J Psychiatr Res. 2013;47(7):865–71.CrossRefPubMed
37.
Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171–86.CrossRefPubMed
38.
Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology. 2003;170(4):429–33.CrossRefPubMed
39.
Tang C-Z, Zhang Y-L, Wang W-S, Li W-G, Shi J-P: Elevated serum levels of neopterin at admission predicts depression after acute ischemic stroke: a 6-month follow-up study. Mol Neurobiol. 2015:1–11. doi:10.​1007/​s12035-015-9220-4.
40.
Lespérance F, Frasure-Smith N, Théroux P, Irwin M. The association between major depression and levels of soluble intercellular adhesion molecule 1, interleukin-6, and C-reactive protein in patients with recent acute coronary syndromes. Am J Psychiatr. 2004;161(2):271–7.CrossRefPubMed
41.
Schaefer M, Horn M, Schmidt F, Schmid-Wendtner MH, Volkenandt M, Ackenheil M, Mueller N, Schwarz MJ. Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-α. Brain Behav Immun. 2004;18(6):555–62.CrossRefPubMed
42.
Motivala SJ, Sarfatti A, Olmos L, Irwin MR. Inflammatory markers and sleep disturbance in major depression. Psychosom Med. 2005;67(2):187–94.CrossRefPubMed
43.
Dimopoulos N, Piperi C, Salonicioti A, Mitsonis C, Liappas I, Lea RW, Kalofoutis A. Elevation of plasma concentration of adhesion molecules in late‐life depression. Int J Geriatr Psychiatry. 2006;21(10):965–71.CrossRefPubMed
44.
Zhan Y, Yang Y-T, You H-M, Cao D, Liu C-Y, Zhou C-J, Wang Z-Y, Bai S-J, Mu J, Wu B. Plasma-based proteomics reveals lipid metabolic and immunoregulatory dysregulation in post-stroke depression. Eur Psychiatry. 2014;29(5):307–15.CrossRefPubMed
45.
Folstein M, Liu T, Peter I, Buel J, Arsenault L, Scott T, Qiu WW. The homocysteine hypothesis of depression. Am J Psychiatr. 2007;164(6):861–7.CrossRefPubMed
46.
Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry. 2000;69(2):228–32.CrossRefPubMedPubMedCentral
47.
Marin RS. Differential diagnosis and classification of apathy. Am J Psychiatry. 1990;147(1):22–30.CrossRefPubMed
48.
Roth RM, Flashman LA, McAllister TW. Apathy and its treatment. Curr Treat Options Neurol. 2007;9(5):363–70.CrossRefPubMed
49.
Withall A, Brodaty H, Altendorf A, Sachdev PS. A longitudinal study examining the independence of apathy and depression after stroke: the Sydney Stroke Study. Int Psychogeriatr. 2011;23(02):264–73.CrossRefPubMed
50.
Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3(3):243–54.CrossRefPubMed
51.
Brodaty H, Sachdev P, Withall A, Altendorf A, Valenzuela M, Lorentz L. Frequency and clinical, neuropsychological and neuroimaging correlates of apathy following stroke: the Sydney Stroke Study. Psychol Med. 2005;35(12):1707–16.CrossRefPubMed
52.
Hama S, Yamashita H, Shigenobu M, Watanabe A, Kurisu K, Yamawaki S, Kitaoka T. Post-stroke affective or apathetic depression and lesion location: left frontal lobe and bilateral basal ganglia. Eur Arch Psychiatry Clin Neurosci. 2007;257(3):149–52.CrossRefPubMed
53.
54.
Andersson S, Krogstad J, Finset A. Apathy and depressed mood in acquired brain damage: relationship to lesion localization and psychophysiological reactivity. Psychol Med. 1999;29(2):447–56.CrossRefPubMed
55.
Okada K, Kobayashi S, Yamagata S, Takahashi K, Yamaguchi S. Poststroke apathy and regional cerebral blood flow. Stroke. 1997;28(12):2437–41.CrossRefPubMed
56.
Mayo NE, Fellows LK, Scott SC, Cameron J, Wood-Dauphinee S. A longitudinal view of apathy and its impact after stroke. Stroke. 2009;40(10):3299–307.CrossRefPubMed
57.
APA. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.
58.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939–939.CrossRefPubMed
59.
Román GC, Tatemichi TK, Erkinjuntti T, Cummings J, Masdeu J, Garcia J, Amaducci L, Orgogozo J-M, Brun A, Hofman A et al. Vascular dementia Diagnostic criteria for research studies: Report of the NINDS‐AIREN International Workshop*. Neurology. 1993;43(2):250–250.CrossRefPubMed
60.
Jorm A. A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): development and cross-validation. Psychol Med. 1994;24(1):145–53.CrossRefPubMed
61.
Nys G, Van Zandvoort M, De Kort P, Jansen B, De Haan E, Kappelle L. Cognitive disorders in acute stroke: prevalence and clinical determinants. Cerebrovasc Dis. 2007;23(5–6):408–16.CrossRefPubMed
62.
Overbeek I, Schruers K, Griez E. Mini international neuropsychiatric interview: Nederlandse versie 5.0.0. DSM-IV [Dutch version] Maastricht. The Netherlands: Universiteit Maastricht; 1999.
63.
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382–9.CrossRefPubMed
64.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70.CrossRefPubMed
65.
Kang H-J, Stewart R, Kim J-M, Jang J-E, Kim S-Y, Bae K-Y, Kim S-W, Shin I-S, Park M-S, Cho K-H et al. Comparative validity of depression assessment scales for screening poststroke depression. J Affect Disord. 2013;147(1–3):186–91.CrossRefPubMed
66.
Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res. 1991;38(2):143–62.CrossRefPubMed
67.
Clarke DE, Ko JY, Kuhl EA, van Reekum R, Salvador R, Marin RS. Are the available apathy measures reliable and valid? A review of the psychometric evidence. J Psychosom Res. 2011;70(1):73–97.CrossRefPubMedPubMedCentral
68.
Cummings JL. The Neuropsychiatric Inventory Assessing psychopathology in dementia patients. Neurology. 1997;48(5 Suppl 6):10S–6S.CrossRef
69.
Aalten P, de Vugt ME, Jaspers N, Jolles J, Verhey FR. The course of neuropsychiatric symptoms in dementia. Part I: findings from the two-year longitudinal Maasbed study. Int J Geriatr Psychiatry. 2005;20(6):523–30.CrossRefPubMed
70.
Kat MG, De Jonghe JF, Aalten P, Kalisvaart C, Dröes R-M, Verhey FR. Neuropsychiatric symptoms of dementia: psychometric aspects of the Dutch version of the Neuropsychiatric Inventory (NPI). Tijdschift voor Gerontologie en Geriatrie. 2002;33:150–5.
71.
Cummings J, McPherson S. Neuropsychiatric assessment of Alzheimer’s disease and related dementias. Aging Clin Exp Res. 2001;13(3):240–6.CrossRef
72.
Herlofson K, Larsen JP. Measuring fatigue in patients with Parkinson's disease: the fatigue severity scale. Eur J Neurol. 2002;9(6):595–600.CrossRefPubMed
73.
Mahoney FI. Functional evaluation: the Barthel index. Md State Med J. 1965;14:61–5.PubMed
74.
Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179–86.CrossRefPubMed
75.
Post MW, Boosman H, Van Zandvoort MM, Passier PE, Rinkel GJ, Visser-Meily JM. Development and validation of a short version of the Stroke Specific Quality of Life Scale. J Neurol Neurosurg Psychiatry. 2011;82(3):283–6.CrossRefPubMed
76.
Costa PT, McCrae RR. The NEO personality inventory: manual, form S and form R. Odessa: Psychological Assessment Resources; 1985.
77.
Aalten P, Ramakers IH, Biessels GJ, de Deyn PP, Koek HL, OldeRikkert MG, Oleksik AM, Richard E, Smits LL, van Swieten JC. The Dutch Parelsnoer Institute-Neurodegenerative diseases; methods, design and baseline results. BMC Neurol. 2014;14(1):254–61.CrossRefPubMedPubMedCentral
78.
Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. Am J Neuroradiol. 1987;8(3):421–6.
79.
de Boer R, Vrooman HA, van der Lijn F, Vernooij MW, Ikram MA, van der Lugt A, Breteler MM, Niessen WJ. White matter lesion extension to automatic brain tissue segmentation on MRI. Neuroimage. 2009;45(4):1151–61.CrossRefPubMed
80.
Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein H, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55(10):967–72.CrossRefPubMedPubMedCentral
81.
82.
Wolz R, Schwarz AJ, Yu P, Cole PE, Rueckert D, Jack CR, Raunig D, Hill D. Robustness of automated hippocampal volumetry across magnetic resonance field strengths and repeat images. Alzheimers Dement. 2014;10(4):430–8.CrossRefPubMed
83.
Carmena R, Duriez P, Fruchart J-C. Atherogenic lipoprotein particles in atherosclerosis. Circulation. 2004;109(23):III-2–7.
84.
Antonios N, Angiolillo DJ, Silliman S. Hypertriglyceridemia and ischemic stroke. Eur Neurol. 2008;60(6):269–78.CrossRefPubMed
85.
Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570–81.CrossRefPubMed
86.
Rasquin S, Verhey F, Van Oostenbrugge R, Lousberg R, Lodder J. Demographic and CT scan features related to cognitive impairment in the first year after stroke. J Neurol Neurosurg Psychiatry. 2004;75(11):1562–7.CrossRefPubMedPubMedCentral
87.
Bour A, Rasquin S, Aben I, Boreas A, Limburg M, Verhey F. A one-year follow-up study into the course of depression after stroke. J Nutr Health Aging. 2010;14(6):488–93.CrossRefPubMed
88.
Arauz A, Rodríguez-Agudelo Y, Sosa AL, Chávez M, Paz F, González M, Coral J, Díaz-Olavarrieta C, Román GC. Vascular cognitive disorders and depression after first-ever stroke: the fogarty-Mexico stroke cohort. Cerebrovasc Dis. 2014;38(4):284–9.CrossRefPubMed
89.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.CrossRefPubMed
90.
Rey A. L'examen clinique en psychologie. Oxford England: Presses Universitaries De France; 1958.
91.
Wechsler D. Wechsler Memory Scale - 3rd edition: Administration and Scoring Manual. San Antonio: The Psychological Corporation; 1997.
92.
Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills. 1958;8(3):271–6.CrossRef
93.
Wilson BA, Alderman N, Burgess PW, Emslie H, Evans JJ. Behavioural assessment of the dysexecutive syndrome (BADS). J Occup Psychol Employ Disabil. 2003;5(2):33–7.
94.
Lezak MD. Neuropsychological assessment. 3rd ed. New York: Oxford University Press; 1995.
95.
Halligan P, Marshall J, Wade D. Visuospatial neglect: underlying factors and test sensitivity. Lancet. 1989;334(8668):908–11.CrossRef
96.
Schmand BA, Bakker D, Saan RJ, Louman J: De Nederlandse Leestest voor Volwassenen: een maat voor het premorbide intelligentieniveau. Tijdschr Gerontol Geriatr. 1991:127–138.
97.
Kaplan E, Goodglass H, Weintraub S. The Boston naming test. 2nd ed. Philadelphia: Lea & Febiger; 1983.
Metadata
Title
The Cognition and Affect after Stroke - a Prospective Evaluation of Risks (CASPER) study: rationale and design
Authors
Elles Douven
Syenna H. J. Schievink
Frans R. J. Verhey
Robert J. van Oostenbrugge
Pauline Aalten
Julie Staals
Sebastian Köhler
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2016
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-016-0588-1

Other articles of this Issue 1/2016

BMC Neurology 1/2016 Go to the issue

Research article

The effect of nucleus basalis magnocellularis deep brain stimulation on memory function in a rat model of dementia

Research article

Development and assessment of a website presenting evidence-based information for people with multiple sclerosis: the IN-DEEP project

Case report

Applied multimodal diagnostics in a case of presenile dementia

Research article

Guillain-Barré syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital discharge database

Erratum

Erratum to: Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with lateral medullary syndrome: case report and literature review

Case report

A case report: Becker muscular dystrophy presenting with epilepsy and dysgnosia induced by duplication mutation of Dystrophin gene